cytochrome P450 2C9; cytochrome P450 BP-1; cytochrome P450 MP-4; S-mephenytoin-4-hydroxylase; limonene 6-monooxygenase; limonene 7-monooxygenase (CYP2C9, CYP2C10)
Jump to navigation
Jump to search
Function
- NADPH-dependent electron transport pathway
- oxidizes a variety of structurally unrelated compounds
- the S isoform of warfarin is a substrate of cyt P450 2C9 the R isoform of limonene is a substrate of cyt P450 2C9
- inducers
- inhibitors
- amiodarone
- cotrimoxazole
- delavirdine
- efavirenz
- etravirine
- fenofibrate
- fluconazole
- fluorouracil
- fluoxetine
- fluvastatin
- fluvoxamine
- gemfibrozil
- Gingko biloba
- imatinib
- isoniazid
- itraconazole
- ketoconazole
- leflunomide
- lovastatin
- Lycium barbarum
- metronidazole
- milk thistle
- modafinil
- oxandrolone
- omeprazole
- paroxetine
- sertraline
- sulfamethoxazole
- ticlopidine
- Vaccinium_macrocarpon (cranberry)
- voriconazole
- zafirlukast
- substrates
- amitriptyline
- carvedilol
- celecoxib
- clomipramine
- desogestrel
- diazepam
- diclofenac
- dronabinol
- etravirine
- fluoxetine
- flurbiprofen
- fluvastatin
- formoterol
- glimepiride
- glipizide
- glyburide
- ibuprofen
- imipramine
- indomethacin
- irbesartan
- losartan
- mefenamic acid
- meloxicam
- methadone
- montelukast
- naproxen
- nateglinide
- omeprazole
- phenytoin
- piroxicam
- ramelteon
- rosiglitazone
- sildenafil
- sulfamethoxazole
- tamoxifen
- tolbutamide
- torsemide
- valdecoxib
- valsartan
- vardenafil
- voriconazole
- warfarin
- zafirlukast
- zileuton
Inhibition:
- among the inhibitors of cyt P450 2C9, fluvoxamine is a strong inhibitor & ketoconazole is a weak inhibitor
Compartment
membrane-bound, endoplasmic reticulum
Expression
rifampin is a strong inducer
Pathology
- CYP2C9 alleles are associated with warfarin resistance
Laboratory
More general terms
Additional terms
References
- ↑ UniProt http://www.uniprot.org/uniprot/P11712.html
- ↑ Cytochrome P450 Allele Nomenclature committee, CYP2C9 alleles http://www.cypalleles.ki.se/cyp2c9.htm
- ↑ Prescriber's Letter Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=150400&pb=PRL (subscription needed) http://www.prescribersletter.com
- ↑ Prescriber's Letter 13(3): 2006 Cytochrome P450 drug interactions Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=220233&pb=PRL (subscription needed) http://www.prescribersletter.com
- ↑ Prescriber's Letter 18(3): 2011 CHART: Cytochrome P450 Drug Interactions Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=270307&pb=PRL (subscription needed) http://www.prescribersletter.com